Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>PRKX</i>, <i>TTBK2</i> and <i>RSK4</i> expression causes sunitinib resistance in kidney carcinoma‐ and melanoma‐cell lines

23 Oct 2011

Abstract excerpt

Resistance to chemotherapeutic agents constitutes a major problem in the treatment of cancer. Over the past years, multi-targeted protein kinase inhibitors such as Gleevec, Sunitinib and Sorafenib are gaining wider acceptance for cancer treatment. These drugs show anti-tumor activity in vitro and in patients. Extended usage of these drugs in therapy commonly results in disease progression due to formation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Mechanisms and Therapy
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22020623
DOI: 10.1002/ijc.26486

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

<i>PRKX</i>, <i>TTBK2</i> and <i>RSK4</i> expression causes sunitinib resistance in kidney carcinoma‐ and melanoma‐cell linesPMID 22020623Read ↗

Strategies to overcome drug resistance of receptor tyrosine kinaseaddicted cancer cells.Semantic proximity Read ↗

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.Semantic proximity Read ↗

Identification of mutations associated with acquired resistance to sunitinib in renal cell cancerSemantic proximity Read ↗

Interaction between Wnt/β-catenin signaling pathway and EMT pathway mediates the mechanism of sunitinib resistance in renal cell carcinomaSemantic proximity Read ↗

Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progressionSemantic proximity Read ↗

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome ReprogrammingSemantic proximity Read ↗

Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic ModificationsSemantic proximity Read ↗

The microRNA signature of patients with sunitinib failure: regulation of <i>UHRF1</i> pathways by <i>microRNA-101</i> in renal cell carcinomaSemantic proximity Read ↗

Resistance to Platinum-Containing Chemotherapy in Testicular Germ Cell Tumors Is Associated with Downregulation of the Protein Kinase SRPK1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.